Akari Therapeutics PLC (AKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akari Therapeutics PLC (AKTX) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.10 Million) by net assets ($22.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Akari Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Akari Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AKTX total debt and obligations for a breakdown of total debt and financial obligations.
Akari Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akari Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Otto Energy Ltd
AU:OEL
|
0.142x |
|
Kadestone Capital Corp
V:KDSX
|
-0.401x |
|
Fondia Oyj
HE:FONDIA
|
-0.113x |
|
Arcure SA
PA:ALCUR
|
0.207x |
|
Diagnos Inc
V:ADK
|
0.539x |
|
Intersport Polska S.A.
WAR:IPO
|
0.401x |
|
Lancashire Holdings Ltd
LSE:LRE
|
0.018x |
|
OXE Marine AB
ST:OXE
|
-0.326x |
Annual Cash Flow Conversion Efficiency for Akari Therapeutics PLC (2010–2024)
The table below shows the annual cash flow conversion efficiency of Akari Therapeutics PLC from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Akari Therapeutics PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.23 Million | $-12.55 Million | -0.565x | -100.79% |
| 2023-12-31 | $-229.00K | $-16.43 Million | 71.755x | +697.63% |
| 2022-12-31 | $1.79 Million | $-21.50 Million | -12.007x | -253.87% |
| 2021-12-31 | $5.55 Million | $-18.85 Million | -3.393x | -87.85% |
| 2020-12-31 | $9.38 Million | $-16.95 Million | -1.806x | +46.36% |
| 2019-12-31 | $3.84 Million | $-12.92 Million | -3.368x | -99.88% |
| 2018-12-31 | $13.38 Million | $-22.54 Million | -1.685x | -6.53% |
| 2017-12-31 | $19.98 Million | $-31.60 Million | -1.582x | -119.04% |
| 2016-12-31 | $34.10 Million | $-24.62 Million | -0.722x | -608.46% |
| 2015-12-31 | $48.72 Million | $-4.97 Million | -0.102x | +94.77% |
| 2014-12-31 | $4.85 Million | $-9.46 Million | -1.950x | -107.97% |
| 2013-12-31 | $5.81 Million | $-5.45 Million | -0.937x | -247.59% |
| 2012-12-31 | $-3.36 Million | $-2.13 Million | 0.635x | +56.57% |
| 2011-12-31 | $-2.48 Million | $-1.01 Million | 0.406x | +124.84% |
| 2010-12-31 | $-2.03 Million | $-366.00K | 0.180x | -- |
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 ant… Read more